Top

Published in:

Open Access 01-06-2019 | Colorectal Cancer | Original Article

Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile

Authors: Daniëlle Krijgsman, Natasja L. de Vries, Anni Skovbo, Morten N. Andersen, Marloes Swets, Esther Bastiaannet, Alexander L. Vahrmeijer, Cornelis J. H. van de Velde, Mirjam H. M. Heemskerk, Marianne Hokland, Peter J. K. Kuppen

Published in: Cancer Immunology, Immunotherapy | Issue 6/2019

Abstract

Objective

As the development and progression of colorectal cancer (CRC) are known to be affected by the immune system, cell subsets such as T cells, natural killer (NK) cells, and natural killer T (NKT) cells are considered interesting targets for immunotherapy and clinical biomarker research. Until now, the role of systemic immune profiles in tumor progression remains unclear. In this study, we aimed to characterize the immunophenotype of circulating T cells, NK cells, and NKT-like cells in patients with CRC, and to subsequently correlate these immunophenotypes to clinical follow-up data.

Methods

Using multiparameter flow cytometry, the subset distribution and immunophenotype of T cells (CD3⁺CD56⁻), CD56^dim NK cells (CD3⁻CD56^dim), CD56^bright NK cells (CD3⁻CD56^bright), and NKT-like (CD3⁺CD56⁺) cells were investigated in peripheral blood mononuclear cell (PBMC) samples from 71 CRC patients and 19 healthy donors.

Results

CRC patients showed profound differences in immune cell subset distribution and their immunophenotype compared to healthy donors, as characterized by increased percentage of regulatory T cells, and reduced expression level of the natural cytotoxicity receptors NKp44 and NKp46 on both CD56^dim NK cells and NKT-like cells. Finally, we showed in a multivariate analysis that above-median percentage of CD16⁺ NKT-like cells was independently associated with shorter disease-free survival in CRC patients.

Conclusion

The altered phenotype of circulating immune cell subsets in CRC and its association with clinical outcome highlight the potential use of PBMC subsets as prognostic biomarkers in CRC, thereby contributing to better insight into the role of systemic immune profiles in tumor progression.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics,2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516. https://doi.org/10.1093/annonc/mds236 CrossRefPubMed

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Suppl 3:iii1–9

Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB et al (2013) Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 19(1):76–85. https://doi.org/10.1177/1753425912453187 CrossRefPubMed

Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC et al (2013) Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med 11:262. https://doi.org/10.1186/1479-5876-11-262 CrossRefPubMedPubMedCentral

Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD et al (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7:7PubMedPubMedCentral

Luckheeram RV, Zhou R, Verma AD, Xia B (2012) CD4(+)T cells: differentiation and functions. Clin Dev Immunol 2012:925135. https://doi.org/10.1155/2012/925135 CrossRefPubMedPubMedCentral

Zhang X, Kelaria S, Kerstetter J, Wang J (2015) The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol 6(3):307–313. https://doi.org/10.3978/j.issn.2078-6891.2015.017 CrossRefPubMedPubMedCentral

Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601:123–131CrossRefPubMed

10.

Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H et al (2002) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 82(12):1725–1733CrossRefPubMed

11.

Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH et al (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118(1):6–10. https://doi.org/10.1002/ijc.21303 CrossRefPubMed

12.

Zeestraten EC, Reimers MS, Saadatmand S, Goossens-Beumer IJ, Dekker JW, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ (2014) Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. BrJCancer 110(2):459–468. https://doi.org/10.1038/bjc.2013.696 CrossRef

13.

Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M et al (2005) Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 42(4):541–546. https://doi.org/10.1016/j.molimm.2004.07.039 CrossRefPubMed

14.

Swets M, König MH, Zaalberg A, Dekker-Ensink NG, Gelderblom H, van de Velde CJ et al (2016) HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. Hum Immunol 77(9):773–779. https://doi.org/10.1016/j.humimm.2016.03.001 CrossRefPubMed

15.

Chang CC, Campoli M, Ferrone S (2005) Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 93:189–234. https://doi.org/10.1016/S0065-230X(05)93006-6 CrossRefPubMed

16.

Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–469. https://doi.org/10.1182/blood-2007-09-077438 CrossRefPubMedPubMedCentral

17.

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510. https://doi.org/10.1038/ni1582 CrossRefPubMed

18.

Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633–640CrossRefPubMed

19.

Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ, Fleuren GJ, Nannmark U, Kuppen PJ (2001) The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 53(2):103–110CrossRefPubMed

20.

Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M et al (2001) Human natural killer cell receptors and co-receptors. Immunol Rev 181:203–214CrossRefPubMed

21.

Dutertre CA, Bonnin-Gelize E, Pulford K, Bourel D, Fridman WH, Teillaud JL (2008) A novel subset of NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function. J Leukoc Biol 84(6):1511–1520. https://doi.org/10.1189/jlb.0608343 CrossRefPubMed

22.

Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S, Malayeri R, Wickremasinghe RG, Davies JK, Lowdell MW (2005) Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology 116(3):354–361. https://doi.org/10.1111/j.1365-2567.2005.02235.x CrossRefPubMedPubMedCentral

23.

Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297–336. https://doi.org/10.1146/annurev.immunol.25.022106.141711 CrossRefPubMed

24.

Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M (1995) Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol 7(7):1157–1161

25.

Krijgsman D, Hokland M, Kuppen PJK (2018) The role of natural killer T cells in cancer-A phenotypical and functional approach. Front Immunol 9:367. https://doi.org/10.3389/fimmu.2018.00367 CrossRefPubMedPubMedCentral

26.

Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC (2001) Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166(11):6477–6482CrossRefPubMed

27.

van den Heuvel MJ, Peralta CG, Hatta K, Han VK, Clark DA (2007) Decline in number of elevated blood CD3(+) CD56(+) NKT cells in response to intravenous immunoglobulin treatment correlates with successful pregnancy. Am J Reprod Immunol 58(5):447–459. https://doi.org/10.1111/j.1600-0897.2007.00529.x CrossRefPubMed

28.

Chan WK, Rujkijyanont P, Neale G, Yang J, Bari R, Das Gupta N, Holladay M, Rooney B, Leung W (2013) Multiplex and genome-wide analyses reveal distinctive properties of KIR+ and CD56+ T cells in human blood. J Immunol 191(4):1625–1636. https://doi.org/10.4049/jimmunol.1300111 CrossRefPubMed

29.

Jiang Y, Cui X, Cui C, Zhang J, Zhou F, Zhang Z, Fu Y, Xu J, Chu Z, Liu J, Han X, Liao C, Wang Y, Cao Y, Shang H (2014) The function of CD3+CD56+ NKT-like cells in HIV-infected individuals. Biomed Res Int 2014:863625. https://doi.org/10.1155/2014/863625 CrossRefPubMedPubMedCentral

30.

Peng LS, Mao FY, Zhao YL, Wang TT, Chen N, Zhang JY, Cheng P, Li WH, Lv YP, Teng YS, Guo G, Luo P, Chen W, Zou QM, Zhuang Y (2016) Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer. Oncotarget 7(34):55222–55230. https://doi.org/10.18632/oncotarget.10484 CrossRefPubMedPubMedCentral

31.

Li XF, Dai D, Song XY, Liu JJ, Zhu L, Zhu X, Ma W, Xu W (2017) A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. Oncol Lett 13(5):3291–3298. https://doi.org/10.3892/ol.2017.5808 CrossRefPubMedPubMedCentral

32.

Kim CH, Johnston B, Butcher EC (2002) Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100(1):11–16. https://doi.org/10.1182/blood-2001-12-0196 CrossRefPubMed

33.

Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what's in a name? Nat Rev Immunol 4(3):231–237. https://doi.org/10.1038/nri1309 CrossRefPubMed

34.

Maecker HT, Trotter J (2006) Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 69(9):1037–1042CrossRefPubMed

35.

Roederer M (2001) Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry 45(3):194–205. https://doi.org/10.1002/1097-0320(20011101)45:3%3c194:AID-CYTO1163%3e3.0.CO;2-C CrossRefPubMed

36.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57(1):289–300

37.

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Pagès F (2014) Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 232(2):199–209CrossRefPubMed

38.

Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35):5944–5951CrossRefPubMed

39.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139 CrossRefPubMed

40.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618. https://doi.org/10.1200/JCO.2010.30.5425 CrossRefPubMed

41.

Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Borger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grutzmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Leonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J (2018) International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135):2128–2139. https://doi.org/10.1016/S0140-6736(18)30789-X CrossRefPubMed

42.

Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K et al (2014) Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med 7(7):1781–1785PubMedPubMedCentral

43.

Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9(2):606–612PubMed

44.

Campbell DJ, Koch MA (2011) Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 11(2):119–130CrossRefPubMedPubMedCentral

45.

Lin YC, Mahalingam J, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Chiu CT, Lin CY (2013) Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer 132(6):1341–1350. https://doi.org/10.1002/ijc.27784 CrossRefPubMed

46.

Gharagozloo M, Rezaei A, Kalantari H, Bahador A, Hassannejad N, Maracy M, Nouri N, Sedghi M, Ghazanfari H, Bayat B (2018) Decline in peripheral blood NKG2D+CD3+CD56+ NKT cells in metastatic colorectal cancer patients. Bratisl Lek Listy 119(1):6–11. https://doi.org/10.4149/BLL_2018_002 CrossRefPubMed

47.

Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, Varesio L, Moretta L, Bosco MC, Vitale M (2013) Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol 43(10):2756–2764. https://doi.org/10.1002/eji.201343448 CrossRefPubMed

48.

Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L (2014) Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44(6):1582–1592. https://doi.org/10.1002/eji.201344272 CrossRefPubMed

49.

Han B, Mao FY, Zhao YL, Lv YP, Teng YS, Duan M, Chen W, Cheng P, Wang TT, Liang ZY, Zhang JY, Liu YG, Guo G, Zou QM, Zhuang Y, Peng LS (2018) Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res 2018:6248590. https://doi.org/10.1155/2018/6248590 CrossRefPubMedPubMedCentral

50.

Valayer A, Brea D, Lajoie L, Avezard L, Combes-Soia L, Labas V, Korkmaz B, Thibault G, Baranek T, Si-Tahar M (2017) Neutrophils can disarm NK cell response through cleavage of NKp46. J Leukoc Biol 101(1):253–259. https://doi.org/10.1189/jlb.3AB0316-140RR CrossRefPubMed

51.

Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, Queirolo P, Vermi W, Facchetti F, Moretta A, Moretta L, Mingari MC, Vitale M (2009) Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A 106(49):20847–20852. https://doi.org/10.1073/pnas.0906481106 CrossRefPubMedPubMedCentral

52.

Li T, Yi S, Liu W, Jia C, Wang G, Hua X, Tai Y, Zhang Q, Chen G (2013) Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med Oncol 30(3):663. https://doi.org/10.1007/s12032-013-0663-z CrossRefPubMed

53.

Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72(6):1407–1415. https://doi.org/10.1158/0008-5472.CAN-11-2544 CrossRefPubMed

54.

Husain Z, Huang Y, Seth P, Sukhatme VP (2013) Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol 191(3):1486–1495. https://doi.org/10.4049/jimmunol.1202702 CrossRefPubMed

55.

Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, Yossef R, Rosenberg LA, Aharoni A, Cerwenka A, Campbell KS, Braiman A, Porgador A (2011) Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 187(11):5693–5702. https://doi.org/10.4049/jimmunol.1102267 CrossRefPubMed

56.

Horton NC, Mathew SO, Mathew PA (2013) Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PLoS One 8(3):e59552. https://doi.org/10.1371/journal.pone.0059552 CrossRefPubMedPubMedCentral

57.

Scurr M, Gallimore A, Godkin A (2012) T cell subsets and colorectal cancer: discerning the good from the bad. Cell Immunol 279(1):21–24. https://doi.org/10.1016/j.cellimm.2012.08.004 CrossRefPubMed

58.

Choi J, Maeng HG, Lee SJ, Kim YJ, Kim DW, Lee HN, Namgung JH, Oh HM, Kim TJ, Jeong JE, Park SJ, Choi YM, Kang YW, Yoon SG, Lee JK (2018) Diagnostic value of peripheral blood immune profiling in colorectal cancer. Ann Surg Treat Res 94(6):312–321. https://doi.org/10.4174/astr.2018.94.6.312 CrossRefPubMedPubMedCentral

59.

Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, Kumar M, Jones S, Rees B, Williams G, Gallimore A, Godkin A (2012) Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8):1163–1171. https://doi.org/10.1136/gutjnl-2011-300970 CrossRefPubMed

60.

Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J (2016) The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology 5(7):e1188243. https://doi.org/10.1080/2162402X.2016.1188243 CrossRefPubMedPubMedCentral

61.

Xu T, Lu J, An H (2017) The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients. Oncotarget 8(65):109079–109093. https://doi.org/10.18632/oncotarget.22606 CrossRefPubMedPubMedCentral

Title: Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile
Authors: Daniëlle Krijgsman
Natasja L. de Vries
Anni Skovbo
Morten N. Andersen
Marloes Swets
Esther Bastiaannet
Alexander L. Vahrmeijer
Cornelis J. H. van de Velde
Mirjam H. M. Heemskerk
Marianne Hokland
Peter J. K. Kuppen
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Colorectal Cancer
Colorectal Cancer
Biomarkers
Published in: Cancer Immunology, Immunotherapy / Issue 6/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02343-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2019

Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas

HCT-116 colorectal cancer cells secrete chemokines which induce chemoattraction and intracellular calcium mobilization in NK92 cells

Systemic and local immunosuppression in patients with high-grade meningiomas

Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer